Pacira Biosciences, Inc. (PCRX)
24.90
+0.82
(+3.41%)
USD |
NASDAQ |
Sep 16, 16:00
24.90
0.00 (0.00%)
After-Hours: 20:00
Pacira Biosciences Enterprise Value : 1.120B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 1.120B |
| September 14, 2026 | 1.144B |
| September 11, 2026 | 1.171B |
| September 10, 2026 | 1.163B |
| September 09, 2026 | 1.192B |
| September 08, 2026 | 1.191B |
| September 04, 2026 | 1.210B |
| September 03, 2026 | 1.220B |
| September 02, 2026 | 1.220B |
| September 01, 2026 | 1.215B |
| August 31, 2026 | 1.192B |
| August 28, 2026 | 1.187B |
| August 27, 2026 | 1.190B |
| August 26, 2026 | 1.192B |
| August 25, 2026 | 1.178B |
| August 24, 2026 | 1.151B |
| August 21, 2026 | 1.144B |
| August 20, 2026 | 1.110B |
| August 19, 2026 | 1.131B |
| August 18, 2026 | 1.117B |
| August 17, 2026 | 1.087B |
| August 14, 2026 | 1.077B |
| August 13, 2026 | 1.084B |
| August 12, 2026 | 1.105B |
| August 11, 2026 | 1.132B |
| Date | Value |
|---|---|
| August 10, 2026 | 1.134B |
| August 07, 2026 | 1.157B |
| August 06, 2026 | 1.180B |
| August 05, 2026 | 1.151B |
| August 04, 2026 | 1.261B |
| August 03, 2026 | 1.233B |
| July 31, 2026 | 1.213B |
| July 30, 2026 | 1.235B |
| July 29, 2026 | 1.212B |
| July 28, 2026 | 1.229B |
| July 27, 2026 | 1.215B |
| July 24, 2026 | 1.192B |
| July 23, 2026 | 1.194B |
| July 22, 2026 | 1.180B |
| July 21, 2026 | 1.188B |
| July 20, 2026 | 1.171B |
| July 17, 2026 | 1.181B |
| July 16, 2026 | 1.181B |
| July 15, 2026 | 1.170B |
| July 14, 2026 | 1.157B |
| July 13, 2026 | 1.178B |
| July 10, 2026 | 1.176B |
| July 09, 2026 | 1.177B |
| July 08, 2026 | 1.177B |
| July 07, 2026 | 1.189B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Zimmer Biomet Holdings, Inc. | 25.83B |
| Liquidia Corp. | 5.754B |
| Johnson & Johnson | 671.76B |
| Merck & Co., Inc. | 401.74B |
| ANI Pharmaceuticals, Inc. | 1.891B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.653M |
| Revenue (Quarterly) | 192.40M |
| Total Expenses (Quarterly) | 187.75M |
| EPS Diluted (Quarterly) | 0.1155 |
| Gross Profit Margin (Quarterly) | 69.60% |
| Profit Margin (Quarterly) | 2.42% |
| Earnings Yield | 1.39% |
| Operating Earnings Yield | 2.63% |
| Normalized Earnings Yield | 1.957 |